Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Matrix Metalloproteinase Inhibition With Doxycycline to Prevent Adverse Remodeling After Acute Myocardial Infarction: A Pilot Study

NCT03508232 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT03508232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03508232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Matrix Metalloproteinase Inhibition With Doxycycline to Prevent Adverse Remodeling After Acute Myocardial Infarction: A Pilot Study
Lead sponsor
University of Alberta
Phase
Phase 2
Overall status
Completed
Start date
January 6, 2020
Completion date
August 26, 2025
Enrollment
174 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, st segment elevation myocardial infarction